Castle Biosciences Inc. (CSTL) Tops Q4 EPS by 22c

Castle Biosciences Inc. (NASDAQ: CSTL) reported Q4 EPS of ($0.25), $0.22 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $25 million versus the consensus estimate of $23.73 million.

GUIDANCE:

Castle Biosciences Inc. sees FY2022 revenue of $115-120 million.

For earnings history and earnings-related data on Castle Biosciences Inc. (CSTL) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Reading (RDI) Tops Q2 EPS by 4c
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c